Mycophenolic acid displays IMPDH-dependent and IMPDH-independent effects on renal fibroblast proliferation and function

Therapeutic Drug Monitoring

Volumn 32, Issue 4, 2010, Pages 405-412

  Petrova, Darinka T ^a   Brandhorst, Gunnar ^a   Brehmer, Franziska ^a   Gross, Oliver ^b   Oellerich, Michael ^a   Armstrong, Victor W ^a  

^a Department of Clinical Chemistry   (Germany)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

COL4A3 deficient mice; COS 7 cells; mycophenolate mofetil; mycophenolic acid; renal fibrosis

Indexed keywords

COLLAGEN TYPE 1; COLLAGEN TYPE 1 ALPHA 1; CONNECTIVE TISSUE GROWTH FACTOR; INOSINATE DEHYDROGENASE; MESSENGER RNA; MYCOPHENOLIC ACID; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; AUTOANTIGEN; COLLAGEN; COLLAGEN TYPE 4; IMMUNOSUPPRESSIVE AGENT; TYPE IV COLLAGEN ALPHA3 CHAIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL FUNCTION; CELL PROLIFERATION; DRUG EFFECT; ENZYME INHIBITION; FIBROBLAST; KIDNEY CELL; KIDNEY DISEASE; KIDNEY FIBROSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WOUND CLOSURE; ANIMAL; CHEMICALLY INDUCED; CHLOROCEBUS AETHIOPS; COS 1 CELL LINE; CYTOLOGY; DOSE RESPONSE; DRUG EFFECTS; EXTRACELLULAR MATRIX; FIBROSIS; GENE EXPRESSION; GENETICS; KIDNEY; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; PHYSIOLOGY; WESTERN BLOTTING; WOUND HEALING;

ANIMALS; AUTOANTIGENS; BLOTTING, WESTERN; CELL PROLIFERATION; CERCOPITHECUS AETHIOPS; COLLAGEN; COLLAGEN TYPE IV; COS CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTRACELLULAR MATRIX; FIBROBLASTS; FIBROSIS; GENE EXPRESSION; IMMUNOSUPPRESSIVE AGENTS; IMP DEHYDROGENASE; KIDNEY; MICE; MICE, KNOCKOUT; MYCOPHENOLIC ACID; WOUND HEALING;

EID: 77955172791     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181e44260     Document Type: Article

References (40)

1. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol. 2008; 214:199-210.
2. Boor P, Sebeková K, Ostendorf T, et al. Treatment targets in renal fibrosis. Nephrol Dial Transplant. 2007;22:3391-3407
3. Mart́?nez-Salgado C, Rodŕ?guez-Peña AB, López-Novoa JM. Involvement of small Ras GTPases and their effectors in chronic renal disease. Cell Mol Life Sci. 2008;65:477-492.
4. Roos N, Poulalhon N, Farge D, et al. In vitro evidence for a direct antifibrotic role of the immunosuppressive drug mycophenolate mofetil. J Pharmacol Exp Ther. 2007;321:583-589.
5. Carr SF, Papp E, Wu JC, et al. Characterization of human type I and type II IMP dehydrogenases. J Biol Chem. 1993;268:27286-27290.
6. Allison AC. Mechanisms of action of mycophenolate mofetil. Lupus. 2005;14(Suppl 1):S2-S8.
7. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000;47:85-118.
8. Hendry BM, Sharpe CC. Targeting Ras genes in kidney disease. Nephron Exp Nephrol. 2003;93:e129-e133.
9. Song J, Lu YP, Luo GH, et al. Effects of mycophenolate mofetil on chronic allograft nephropathy by affecting RHO/ROCK signal pathways. Transplant Proc. 2008;40:2790-2794.
10. Shipkova M, Armstrong VW, Oellerich M, et al. Mycophenolate mofetil in organ transplantation: focus on metabolism, safety and tolerability. Expert Opin Drug Metab Toxicol. 2005;1:505-526.
11. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet. 2007;46:13-58.
12. Lipsky JJ. Mycophenolate mofetil. Lancet. 1996;348:1357-1359.
13. Meier-Kriesche HU, Li S, Gruessner RW, et al. Immunosuppression: evolution in practice and trends, 1994-2004. Am J Transplant. 2006;6: 1111-1131.
14. Oellerich M, Shipkova M, Schutz E, et al. Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: implications for therapeutic drug monitoring. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. Ther Drug Monit. 2000;22: 20-26.
15. Johnsson C, Gerdin B, Tufveson G. Effects of commonly used immunosuppressants on graft-derived fibroblasts. Clin Exp Immunol. 2004;136:405-412.
16. Waller JR, Brook NR, Bicknell GR, et al. Mycophenolate mofetil inhibits intimal hyperplasia and attenuates the expression of genes favouring smooth muscle cell proliferation and migration. Transplant Proc. 2005; 37:164-166.
17. Badid C, Vincent M, McGregor B, et al. Mycophenolate mofetil reduces myofibroblast infiltration and collagen III deposition in rat remnant kidney. Kidney Int. 2000;58:51-61.
18. Miljkovic DJ, Samardzic T, Drakulic D, et al. Immunosuppressants leflunomide and mycophenolic acid inhibit fibroblast IL-6 production by distinct mechanisms. Cytokine. 2002;19:181-186.
19. Baer PC, Wegner B, Geiger H. Effects of mycophenolic acid on IL-6 expression of human renal proximal and distal tubular cells in vitro. Nephrol Dial Transplant. 2004;19:47-52.
20. Weimer R, Mytilineos J, Feustel A, et al. Mycophenolate mofetil-based immunosuppression and cytokine genotypes: effects on monokine secretion and antigen presentation in long-term renal transplant recipients. Transplantation. 2003;75:2090-2099.
21. Kaminska D, Tyran B, Mazanowska O, et al. Mycophenolate mofetil but not the type of calcineurin inhibitor (cyclosporine vs tacrolimus) influences the intragraft mRNA expression of cytokines in human kidney allograft biopsies by in situ RT-PCR analysis. Transplant Proc. 2005;37:770-772.
22. Fujihara CK, Noronha IL, Malheiros, et al. Combined mycophenolate mofetil and losartan therapy arrests established injury in the remnant kidney. J Am Soc Nephrol. 2000;11:283-290.
23. Gonxcalves RG, Biato MA, Colosimo RD, et al. Effects of mycophenolate mofetil and lisinopril on collagen deposition in unilateral ureteral obstruction in rats. Am J Nephrol. 2004;24:527-536.
24. Krämer S, Loof T, Martini S, et al. Mycophenolate mofetil slows progression in anti-thy1-induced chronic renal fibrosis but is not additive to a high dose of enalapril. Am J Physiol Renal Physiol. 2005; 289:F359-F368.
25. Romero F, Rodŕ?guez-Iturbe B, Parra G, et al. Mycophenolate mofetil prevents the progressive renal failure induced by 5/6 renal ablation in rats. Kidney Int. 1999;55:945-955.
26. Brandhorst G, Brehmer F, Petrova DT, et al. Mycophenolic acid predose concentrations and renal function in a mouse model for progressive renal fibrosis. Ther Drug Monit. 2010;32:73-78.
27. Javelaud D, Laboureau J, Gabison E, et al. Disruption of basal JNK activity differentially affects key fibroblast functions important for wound healing. J Biol Chem. 2003;278:24624-24628.
28. Petrova DT, Heller T, Hitt R, et al. Regulation of IL2 and NUCB1 in mononuclear cells treated with acyl glucuronide of mycophenolic acid reveals effects independent of inosine monophosphate dehydrogenase inhibition. Ther Drug Monit. 2009;31:31-41.
29. Grinnell F. Fibroblasts, myofibroblasts, and wound contraction. J Cell Biol. 1994;124:401-404.
30. Cooker LA, Peterson D, Rambow J, et al. TNF-alpha, but not IFN-gamma, regulates CCN2 (CTGF), collagen type I, and proliferation in mesangial cells: possible roles in the progression of renal fibrosis. Am J Physiol Renal Physiol. 2007;293:F157-F165.
31. Zhou G, Li C, Cai L. Advanced glycation end-products induce connective tissue growth factor-mediated renal fibrosis predominantly through transforming growth factor beta-independent pathway. Am J Pathol. 2004;165:2033-2043.
32. Frazier K, Williams S, Kothapalli D, et al. Stimulation of fibroblast cell growth, matrix production, and granulation tissue formation by connective tissue growth factor. J Invest Dermatol. 1996;107:404-411.
33. Kobayashi T, Inoue T, Okada H, et al. Connective tissue growth factor mediates the profibrotic effects of transforming growth factor-beta produced by tubular epithelial cells in response to high glucose. Clin Exp Nephrol. 2005;9:114-121.
34. Nicholson ML, Waller JR, Bicknell GR. Renal transplant fibrosis correlates with intragraft expression of tissue inhibitor of metal-loproteinase messenger RNA. Br J Surg. 2002;89:933-937.
35. Boldt A, Barten MJ, Weiss C, et al. Novel apoptosis assay to analyze immunosuppression. Cytometry A. 2006;69:158-160.
36. Heller T, Asif AR, Petrova DT, et al. Differential proteomic analysis of lymphocytes treated with mycophenolic acid reveals caspase 3-induced cleavage of rho GDP dissociation inhibitor 2. Ther Drug Monit. 2009;31: 211-217.
37. Clancy RM, Buyon JP. Clearance of apoptotic cells: TGF-beta in the balance between inflammation and fibrosis. J Leukoc Biol. 2003;74:959-960.
38. Huang XR, Chung AC, Wang XJ, et al. Mice overexpressing latent TGF-beta1 are protected against renal fibrosis in obstructive kidney disease. Am J Physiol Renal Physiol. 2008;295:F118-F127.
39. Daniel C, Takabatake Y, Mizui M, et al. Antisense oligonucleotides against thrombospondin-1 inhibit activation of TGF-beta in fibrotic renal disease in the rat in vivo. Am J Pathol. 2003;163:1185-1192.
40. Grinnell F. Fibroblast-collagen-matrix contraction: growth-factor signalling and mechanical loading. Trends Cell Biol. 2000;10:362-365.